Understanding Residual Cardiovascular Risk in CKD and T2D
Diabetes DiscourseUnderstanding Residual Cardiovascular Risk in CKD and T2D
John W. Ostrominski, MD, MPH
Efficacy and Safety of Finerenone in Patients With Non-Diabetic CKD: Insight From FIND-CKD
NephrologyEfficacy and Safety of Finerenone in Patients With Non-Diabetic CKD: Insight From FIND-CKD
prof. Hiddo Heerspink
Finerenone Efficacy and Safety in Patients With CKD Regardless of Diabetes Status: Insights From the INFINITY Dataset
NephrologyFinerenone Efficacy and Safety in Patients With CKD Regardless of Diabetes Status: Insights From the INFINITY Dataset
Rajiv Agarwal, MBBS, MD, FASN, BRCU
Finerenone Subgroup Analyses in Patients With Glomerulonephritis
NephrologyFinerenone Subgroup Analyses in Patients With Glomerulonephritis
Brendon Neuen, MBBS, PhD
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
Heart MattersA Multi-Pillar Approach to Cardio-Renal Risk Reduction
Brian P. McDonough, MD, FAAFP
Anu Lala, MD
Martha Gulati, MD, MS, FACC, FAHA
Proteinuria First: Managing What Matters in FSGS
KDIGO Conversations in NephrologyProteinuria First: Managing What Matters in FSGS
Kirk Campbell, MD
Laura H. Mariani, MD, MS,FASN
- advertisement
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
CME/CETranslating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Patrick Rossignol, MD, PhD
Julio Núñez, MD, PhD
Aldosterone-Targeted Therapies for Uncontrolled Hypertension in Chronic Kidney Disease
CME/CEAldosterone-Targeted Therapies for Uncontrolled Hypertension in Chronic Kidney Disease
Jamie P. Dwyer, MD
J. Matthew Luther, MD, MSCI
Vivek Bhalla, MD
Continuing the Search: New Data on Hypercortisolism Prevalence in Difficult-to-Control Metabolic Conditions
CME/CEContinuing the Search: New Data on Hypercortisolism Prevalence in Difficult-to-Control Metabolic Conditions
Christian Mende, MD, FACP, FACN, FASN, FASH, FAHA
Deepak Bhatt, MD, MPH, MBA, FACC, FAHA
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
CME/CENavigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Chee Kay Cheung, MBChB, PhD, FRCP
Claudia Seikrit, MD
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
CME/CEVous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
CME/CETransforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP
Ankana Daga, MD
- advertisement
Rethinking Cardiovascular Risk: Uncovering the Blind Spots
Conversations in CV Risk AssessmentRethinking Cardiovascular Risk: Uncovering the Blind Spots
Jennifer Caudle, DO, FACOFP
Javed Butler, MD, MPH, MBA
Elevating CV Risk Assessment: Why uACR Deserves a Seat at the Table
Conversations in CV Risk AssessmentElevating CV Risk Assessment: Why uACR Deserves a Seat at the Table
Brian P. McDonough, MD, FAAFP
Javier Morales, MD, FACP, FACE
Primary Care and Cardiology: Shared Responsibility in Albuminuria Detection
Conversations in CV Risk AssessmentPrimary Care and Cardiology: Shared Responsibility in Albuminuria Detection
Jennifer Caudle, DO, FACOFP
Javed Butler, MD, MPH, MBA
Martha Gulati, MD, MS, FACC, FAHA
Challenging Cases in IgA Nephropathy and Identifying Patients for Specialized Care
Medical Industry FeatureChallenging Cases in IgA Nephropathy and Identifying Patients for Specialized Care
Jaimini Patel, PharmD, BCCCP
Sayna Norouzi, MD
The Role of APRIL and the 4-Hit Process in the Pathogenesis of IgA Nephropathy
Medical Industry FeatureThe Role of APRIL and the 4-Hit Process in the Pathogenesis of IgA Nephropathy
Edgar V. Lerma, MD, FACP, FASN, FPSN (Hon)
Luis E. Vélez, MD
Navigating IgA Nephropathy: Pathogenesis, The Role Of APRIL & The 4-Hit Process, & A Patient Case Study
Medical Industry FeatureNavigating IgA Nephropathy: Pathogenesis, The Role Of APRIL & The 4-Hit Process, & A Patient Case Study
Abigail Yancey, PharmD, BCPS
Kartik Kalra, MD
- 06/11/2026
- 06/10/2026
- 06/09/2026
- 06/09/2026
- 06/08/2026
- 06/08/2026